A phase 3 trial of a higher-dose CagriSema formulation at 2.4/7.2 mg is planned for initiation in the second half of 2026, and the REDEFINE 11 trial, exploring CagriSemas full weight-loss potential, is expected to report data in the first half of 2027
This combination therapy addresses multiple pathways, making it a robust solution for patients with type 2 diabetes and obesity
Guehring T, Urban JP, Cui Z, Tirlapur UK: Noninvasive 3D vital imaging and characterization of notochordal cells of the intervertebral disc by femtosecond near-infrared two-photon laser scanning microscopy and spatial-volume rendering
Wipe down your work surface
For readers comparing options, our overview of the supervised peptide therapy options available through Perfect Bs treatment plan in Doral, FL explains how a clinical program differs from sourcing compounds independently